Target Price | CHF805.80 |
Price | CHF835.40 |
Deviation | 3.54% |
Number of Estimates | 14 |
14 Analysts have issued a price target Swiss Life 2026 . The average Swiss Life target price is CHF805.80. This is 3.54% lower than the current stock price. The highest price target is CHF945.00 13.12% , the lowest is CHF681.75 18.39% . | |
A rating was issued by 19 analysts: 9 Analysts recommend Swiss Life to buy, 7 to hold and 3 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Swiss Life stock has an average upside potential 2026 of 3.54% . Most analysts recommend the Swiss Life stock at Purchase. |
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Billion CHF | 10.92 | 17.78 |
16.63% | 62.91% | |
Net Margin | 11.12% | 7.26% |
34.46% | 34.73% |
8 Analysts have issued a sales forecast Swiss Life 2025 . The average Swiss Life sales estimate is CHF17.8b . This is 62.91% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF24.6b 125.12% , the lowest is CHF3.4b 68.87% .
This results in the following potential growth metrics:
2024 | CHF10.9b | 16.63% |
---|---|---|
2025 | CHF17.8b | 62.91% |
2026 | CHF22.0b | 23.59% |
2027 | CHF19.3b | 12.40% |
2028 | CHF9.5b | 50.69% |
2029 | CHF9.6b | 1.50% |
2030 | CHF9.8b | 1.49% |
2031 | CHF9.9b | 1.50% |
2032 | CHF10.1b | 1.50% |
14 Swiss Life Analysts have issued a net profit forecast 2025. The average Swiss Life net profit estimate is CHF1.3b . This is 6.37% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF1.4b 16.22% , the lowest is CHF1.1b 5.85% .
This results in the following potential growth metrics and future Net Margins:
2024 | CHF1.2b | 12.10% |
---|---|---|
2025 | CHF1.3b | 6.37% |
2026 | CHF1.4b | 8.14% |
2027 | CHF1.5b | 6.17% |
2028 | CHF1.6b | 6.87% |
2029 | CHF1.7b | 5.63% |
2030 | CHF1.8b | 6.69% |
2031 | CHF2.0b | 9.57% |
2032 | CHF2.1b | 6.58% |
2024 | 11.12% | 34.46% |
---|---|---|
2025 | 7.26% | 34.73% |
2026 | 6.35% | 12.53% |
2027 | 7.70% | 21.26% |
2028 | 16.69% | 116.75% |
2029 | 17.37% | 4.07% |
2030 | 18.26% | 5.12% |
2031 | 19.71% | 7.94% |
2032 | 20.70% | 5.02% |
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share CHF | 42.29 | 45.26 |
14.27% | 7.02% | |
P/E | 18.46 | |
EV/Sales | 1.59 |
14 Analysts have issued a Swiss Life forecast for earnings per share. The average Swiss Life EPS is CHF45.26 . This is 8.33% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF49.46 18.38% , the lowest is CHF40.06 4.12% .
This results in the following potential growth metrics and future valuations:
2024 | CHF42.29 | 14.27% |
---|---|---|
2025 | CHF45.26 | 7.02% |
2026 | CHF48.95 | 8.15% |
2027 | CHF51.97 | 6.17% |
2028 | CHF55.53 | 6.85% |
2029 | CHF58.66 | 5.64% |
2030 | CHF62.59 | 6.70% |
2031 | CHF68.58 | 9.57% |
2032 | CHF73.09 | 6.58% |
Current | 20.00 | 11.31% |
---|---|---|
2025 | 18.46 | 7.68% |
2026 | 17.07 | 7.53% |
2027 | 16.08 | 5.80% |
2028 | 15.04 | 6.47% |
2029 | 14.24 | 5.32% |
2030 | 13.35 | 6.25% |
2031 | 12.18 | 8.76% |
2032 | 11.43 | 6.16% |
Based on analysts' sales estimates for 2025, the Swiss Life stock is valued at an EV/Sales of 1.59 and an P/S ratio of 1.35 .
This results in the following potential growth metrics and future valuations:
Current | 2.59 | 2.78% |
---|---|---|
2025 | 1.59 | 38.56% |
2026 | 1.29 | 19.09% |
2027 | 1.47 | 14.16% |
2028 | 2.98 | 102.78% |
2029 | 2.94 | 1.47% |
2030 | 2.89 | 1.47% |
2031 | 2.85 | 1.48% |
2032 | 2.81 | 1.48% |
Current | 2.19 | 29.99% |
---|---|---|
2025 | 1.35 | 38.62% |
2026 | 1.09 | 19.08% |
2027 | 1.24 | 14.16% |
2028 | 2.52 | 102.77% |
2029 | 2.48 | 1.47% |
2030 | 2.45 | 1.47% |
2031 | 2.41 | 1.48% |
2032 | 2.38 | 1.48% |
Analyst | Rating | Action | Date |
---|---|---|---|
BERENBERG |
Buy
➜
Buy
|
Unchanged | Jul 06 2025 |
BERENBERG |
Buy
➜
Buy
|
Unchanged | Mar 31 2025 |
DAY BY DAY |
Buy
➜
Buy
|
Unchanged | Feb 05 2025 |
BERENBERG |
Buy
➜
Buy
|
Unchanged | Dec 12 2024 |
BNP PARIBAS EXANE |
Outperform
➜
Outperform
|
Unchanged | Dec 08 2024 |
HSBC |
Hold
➜
Hold
|
Unchanged | Nov 24 2024 |
Analyst Rating | Date |
---|---|
Unchanged
BERENBERG:
Buy
➜
Buy
|
Jul 06 2025 |
Unchanged
BERENBERG:
Buy
➜
Buy
|
Mar 31 2025 |
Unchanged
DAY BY DAY:
Buy
➜
Buy
|
Feb 05 2025 |
Unchanged
BERENBERG:
Buy
➜
Buy
|
Dec 12 2024 |
Unchanged
BNP PARIBAS EXANE:
Outperform
➜
Outperform
|
Dec 08 2024 |
Unchanged
HSBC:
Hold
➜
Hold
|
Nov 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.